A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

Clinical trial NCT06799026 · RECRUITING

Trial details

NCT number: NCT06799026
Sponsor: David Avigan
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Multiple Myeloma Relapse Multiple Myeloma Refractory Multiple Myeloma

Start date: 2025-01-31
Primary completion: 2028-09-01
Enrollment: 25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.